These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 18176695

  • 1. Treatment outcome of tuberculosis patients diagnosed with human immunodeficiency virus infection in Iran.
    Tabarsi P, Baghaei P, Mirsaeidi M, Amiri M, Alipanah N, Emami H, Novin A, Mansouri D, Masjedi MR, Velayati AA.
    Saudi Med J; 2008 Jan; 29(1):148-50. PubMed ID: 18176695
    [No Abstract] [Full Text] [Related]

  • 2. Clinical experience with rifabutin in the treatment of mycobacterial infections.
    De Cian W, Sassella D, Wynne BA.
    Scand J Infect Dis Suppl; 1995 Jan; 98():22-6. PubMed ID: 8867175
    [Abstract] [Full Text] [Related]

  • 3. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis.
    Burman W, Weis S, Vernon A, Khan A, Benator D, Jones B, Silva C, King B, LaHart C, Mangura B, Weiner M, El-Sadr W.
    Int J Tuberc Lung Dis; 2007 Dec; 11(12):1282-9. PubMed ID: 18229435
    [Abstract] [Full Text] [Related]

  • 4. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2000 Mar 10; 49(9):185-9. PubMed ID: 11795500
    [Abstract] [Full Text] [Related]

  • 5. Survival of a large cohort of HIV-infected tuberculosis patients in the era of highly active antiretroviral treatment.
    Català L, Orcau A, García de Olalla P, Millet JP, Rodríguez-Mondragón A, Caylà JA, TB-HIV Working Group.
    Int J Tuberc Lung Dis; 2011 Feb 10; 15(2):263-9, i. PubMed ID: 21219692
    [Abstract] [Full Text] [Related]

  • 6. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2002 Mar 15; 51(10):214-5. PubMed ID: 11922192
    [Abstract] [Full Text] [Related]

  • 7. Uveitis associated with rifabutin therapy: a clinical alert.
    Petrowski JT.
    J Am Optom Assoc; 1996 Nov 15; 67(11):693-6. PubMed ID: 8979664
    [Abstract] [Full Text] [Related]

  • 8. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
    Benator DA, Weiner MH, Burman WJ, Vernon AA, Zhao ZA, Khan AE, Jones BE, Sandman L, Engle M, Silva-Trigo C, Hsyu PH, Becker MI, Peloquin CA, Tuberculosis Trials Consortium.
    Pharmacotherapy; 2007 Jun 15; 27(6):793-800. PubMed ID: 17542762
    [Abstract] [Full Text] [Related]

  • 9. Protease inhibitors and rifabutin: isn't the jury still out?
    Jenny-Avital ER.
    Clin Infect Dis; 2001 Jan 15; 32(2):322-3. PubMed ID: 11170931
    [No Abstract] [Full Text] [Related]

  • 10. Issues in the management of HIV-related tuberculosis.
    Burman WJ.
    Clin Chest Med; 2005 Jun 15; 26(2):283-94, vi-vii. PubMed ID: 15837111
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Review editorial: prevention of tuberculosis in resource-poor countries with increasing access to highly active antiretroviral treatment.
    Apers L, Lynen L, Worodria W, Colebunders R.
    Trop Med Int Health; 2005 Dec 15; 10(12):1209-14. PubMed ID: 16359399
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
    Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, Ashkin D, Symes S, Espinoza LA, Rivero RO, Graham JJ, Peloquin CA.
    Clin Infect Dis; 2009 Nov 01; 49(9):1305-11. PubMed ID: 19807276
    [Abstract] [Full Text] [Related]

  • 14. Drugs for tuberculosis.
    Treat Guidel Med Lett; 2004 Dec 01; 2(28):83-8. PubMed ID: 15557876
    [No Abstract] [Full Text] [Related]

  • 15. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
    Jenny-Avital ER, Joseph K.
    Clin Infect Dis; 2009 May 15; 48(10):1471-4. PubMed ID: 19368504
    [Abstract] [Full Text] [Related]

  • 16. Rifabutin.
    Tuberculosis (Edinb); 2008 Mar 15; 88(2):145-7. PubMed ID: 18486056
    [No Abstract] [Full Text] [Related]

  • 17. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida.
    Enferm Infecc Microbiol Clin; 2009 Apr 15; 27(4):222-35. PubMed ID: 19246124
    [Abstract] [Full Text] [Related]

  • 18. A regimen containing rifabutin for the treatment of tuberculosis in patients intolerant to rifampin.
    Tattevin P, Revest M, Dupont M, Arvieux C, Michelet C.
    Clin Infect Dis; 2003 Jan 01; 36(1):127-8. PubMed ID: 12491218
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Criteria for use of rifabutin in adult patients with human immunodeficiency virus (HIV)-associated disease.
    Fish N, Kass CL.
    Am J Health Syst Pharm; 1996 Jul 01; 53(13):1598-9. PubMed ID: 8809283
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.